8-K: CDT Equity Engages Bio-Advisory Firms for Asset Licensing

CDT Equity Inc. has entered into two consulting agreements to enhance its pre-clinical development and accelerate out-licensing opportunities for its solid-form patent portfolio.

Summary

• CDT Equity Inc. entered into a Consulting Agreement with Thesprogen, PC on December 28, 2025, for a six-month term.
• Thesprogen will evaluate pre-clinical data on AZD1656, devise strategies for optimizing pre-clinical development (including human organ models for COPD, IPF, NASH, Kidney), and improve public messaging.
• CDT issued 108,392 shares of common stock, valued at $155,000, to Thesprogen as compensation, effective December 29, 2025.
• CDT also entered into a Consulting Agreement with NJS Foresight Bio-Advisory, LLC on December 29, 2025, for a twelve-month term.
• NJS will provide advisory and business development services, focusing on identifying and supporting potential licensing partners for CDT's asset portfolio.
• NJS received an initial retainer of $150,000, paid by issuing 104,896 shares of common stock, effective December 29, 2025.
• NJS is eligible for an 8% commission fee on the total announced value of any out-licensing transaction executed during the term, with a 12-month tail period for introduced and materially negotiated transactions.
• The shares issued to both consultants were unregistered sales of equity securities, relying on Section 4(a)(2) and/or Rule 506 of Regulation D.

Sentiment

Score: 7

Explanation: The filing indicates proactive steps by management to advance its asset portfolio and pursue strategic partnerships, which is generally positive. The engagement of experienced consultants for both scientific development and business development suggests a focused effort to unlock value. However, the issuance of shares for compensation, while common, represents some dilution, and the success of these initiatives is forward-looking and subject to execution risks.

Positives

• Engaging specialized consultants to optimize pre-clinical development and public messaging for AZD1656, a key asset.
• Partnering with NJS Foresight Bio-Advisory, which brings over 20 years of out-licensing experience and a principal with 25+ years of clinical and pharmaceutical/biotechnology expertise, to accelerate asset out-licensing.
• Leveraging a solid-form patent portfolio that offers enhanced physicochemical properties and up to 20 years of patent protection, potentially extending product lifecycles for partners.
• Positioning the company to capitalize on increased biopharma investment activity driven by patent expirations, consolidation, and AI adoption.
• Management sees strong potential for solid-form assets to support lifecycle management strategies across the sector.

Negatives

• Issuance of common stock to consultants could lead to dilution for existing shareholders.
• Reliance on unregistered sales of equity securities means these shares are restricted and not freely tradable without registration or an exemption.
• The commission-based structure for NJS means potentially significant future payments, which could be in cash or further stock, depending on the company's election.

Risks

• The effect that a reverse stock split may have on the price of the company's common stock.
• The ability or inability to maintain the listing of CDT's securities on Nasdaq.
• The ability to recognize the anticipated benefits of the business combination completed in September 2023, which may be affected by competition.
• The ability of the combined company to grow and manage growth economically and hire and retain key employees.
• Risks that product candidates in development fail clinical trials or are not approved by regulatory authorities on a timely basis or at all.
• Changes in applicable laws or regulations.
• The possibility that CDT may be adversely affected by other economic, business, and/or competitive factors.
• Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially.

Future Outlook

The company aims to unlock value from its solid-form asset portfolio by expanding commercial reach and accelerating potential licensing and royalty-based transactions through strategic partnerships. It believes current industry trends, such as patent expirations, strategic consolidation, and AI adoption, create a favorable environment for solid-form innovation and out-licensing. The CEO sees strong potential for solid-form assets to support lifecycle management strategies across the biopharmaceutical sector.

Management Comments

• "CDT continues to assess commercial pathways for its portfolio and sees strong potential for its solid-form assets to support lifecycle management strategies across the sector." Dr. Andrew Regan, Chief Executive Officer of CDT.

Industry Context

The biopharmaceutical industry is experiencing a renewed period of investment activity, driven by factors such as upcoming patent expirations for existing drugs, strategic consolidation among companies, and the increasing adoption of AI-driven technologies in drug discovery and development. This environment is seen as constructive for companies like CDT Equity Inc. that focus on solid-form innovation and out-licensing, as their assets can help partners extend product lifecycles and address market needs.

Stakeholder Impact

• Shareholders: Potential for dilution from current and future stock issuances to consultants. Potential for increased shareholder value if consulting agreements lead to successful asset development and out-licensing deals.
• Employees: No direct impact mentioned, but successful strategic initiatives could lead to growth opportunities.
• Customers/Partners: Potential for new partnerships and expanded reach for CDT's solid-form assets.

Next Steps

• Thesprogen, PC will commence services on January 1, 2026, to evaluate pre-clinical data on AZD1656 and devise optimization strategies.
• NJS Foresight Bio-Advisory, LLC will commence services on December 30, 2025, to identify, introduce, and support potential licensing partners for CDT's asset portfolio.
• CDT will continue to assess commercial pathways for its portfolio.
• CDT aims to accelerate potential licensing and royalty-based transactions.

Key Dates

Recommendation

The filing outlines strategic engagements aimed at enhancing asset development and unlocking value through out-licensing. While these are positive steps, the immediate impact on financial performance is not detailed, and the success of these initiatives is inherently forward-looking and subject to execution risks. The issuance of shares for compensation introduces some dilution. Given the strategic nature of the agreements and the potential for future value creation balanced against the inherent risks and lack of immediate financial results, a 'hold' recommendation is appropriate for investors to observe the outcomes of these new partnerships.

Keywords

Biopharmaceutical, Out-licensing, Consulting Agreement, Solid-form chemistry, Patent portfolio, Pre-clinical development, AZD1656, Equity issuance, Nasdaq, Biotech, Pharmaceutical, Drug development, Intellectual property, Strategic partnerships